Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan to Reduce Urinary Supersaturation
NCT02096965Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tolvaptan in nephrolithiasis (2 arms), sponsored by Mayo Clinic. Primary endpoints: Change in urinary calcium oxalate supersaturation at 3 weeks and Change in Calcium phosphate SS at 3 weeks. Started Mar 2014; status: completed.
02
Drugs
tolvaptan
03
Conditions
nephrolithiasis
Beyond the preview
Go deeper on NCT02096965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096965.